Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.

Clinical lung cancer - 1 Jan 2022

Hayashi Hidetoshi, Nadal Ernest, Gray Jhanelle E, Ardizzoni Andrea, Caria Nicola, Puri Tarun, Grohe Christian

Abstract excerpt

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are standard of care in the first-line (1L) setting for patients with metastatic non-small cell lung cancer (mNSCLC) with activating EGFR mutations. EGFR-activating mutations are a predictive factor for response to EGFR-TKIs. Meta-analyses have shown that patients with exon 21_L858R mutations exhibit reduced sensitivity to EGFR-TKIs,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Combinations

Share to Genes, erbB-1

Share to Lung Neoplasms

Share to Neoplasm Metastasis

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 34865963
DOI: 10.1016/j.cllc.2021.10.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.PMID 34865963Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Treatment sequences in EGFR mutant advanced NSCLC.Semantic proximity Read ↗

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer.Semantic proximity Read ↗

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Semantic proximity Read ↗

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.Semantic proximity Read ↗

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients.Semantic proximity Read ↗

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.Semantic proximity Read ↗

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative ReviewSemantic proximity Read ↗

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.